Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCaP: Allogeneic CMV-specific T Cells and Pembrolizumab in Glioblastoma Multiforme
NCT06157541Phase 2Active, not recruiting
- Sponsor
- QIMR Berghofer Medical Research Institute
- Start
- Feb 2024
- Primary completion
- Oct 2025
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
A Phase 2 trial of adimlecleucel in glioblastoma multiforme (GBM), astrocytoma, sponsored by QIMR Berghofer Medical Research Institute. Started Feb 2024; status: active, not recruiting.
02
Drugs
adimlecleucel
03
Conditions
glioblastoma multiforme (GBM)astrocytoma
Beyond the preview
Go deeper on NCT06157541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06157541.